Victory Capital Management Inc. Sells 113,193 Shares of Integer Holdings Co. (NYSE:ITGR)

Victory Capital Management Inc. lessened its holdings in Integer Holdings Co. (NYSE:ITGR) by 18.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 514,693 shares of the medical equipment provider’s stock after selling 113,193 shares during the quarter. Victory Capital Management Inc.’s holdings in Integer were worth $68,207,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Mather Group LLC. boosted its stake in shares of Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Huntington National Bank boosted its stake in shares of Integer by 8,933.3% in the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 268 shares during the last quarter. R Squared Ltd bought a new position in shares of Integer in the 4th quarter valued at about $44,000. Versant Capital Management Inc raised its position in shares of Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 183 shares during the period. Finally, Principal Securities Inc. raised its position in shares of Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 152 shares during the period. Institutional investors own 99.29% of the company’s stock.

Integer Stock Performance

Shares of ITGR stock opened at $121.84 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The company has a market capitalization of $4.10 billion, a P/E ratio of 36.26, a price-to-earnings-growth ratio of 1.72 and a beta of 1.13. The company’s 50 day moving average price is $135.73 and its two-hundred day moving average price is $132.87. Integer Holdings Co. has a 52 week low of $107.11 and a 52 week high of $146.36.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. On average, analysts expect that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

ITGR has been the topic of a number of analyst reports. KeyCorp increased their price target on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Citigroup increased their price target on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. Oppenheimer downgraded shares of Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Finally, Benchmark increased their price target on shares of Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Integer presently has an average rating of “Moderate Buy” and a consensus target price of $147.67.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.